Compare Abbott Laboratories (ABT) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Rush Street Interactive Inc — how do they compare? Abbott Laboratories trades at $110.97 (market cap $187.95B), while Rush Street Interactive Inc trades at $24.24 (market cap $2.91B). The key difference: Abbott Laboratories is far larger — about 64.6× Rush Street Interactive Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.
| ABT | RSI | |
|---|---|---|
Market Cap | $187.95B | $2.91B |
Sector | Health | Technology |
52-Week High | $136.62 | $34.52 |
52-Week Low | $82.57 | $15.89 |
Enterprise Value | $214.96B | $2.57B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Rush Street Interactive (RSI) trades at $24.28, down 1.78% over 24 hours, with a bearish technical signal from moving averages despite bullish oscillators. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Financials show strong revenue growth but thin net margins of 2.33%, with elevated valuation ratios like a P/E of 81.13. Analyst consensus is strongly bullish with a $34.75 price target.
The outlook is positive due to robust revenue growth and expansion in online casino and sports betting markets, but risks include high valuation sensitivity and competitive pressures. Institutional buying by firms like Dimensional Fund Advisors supports sentiment, though insider selling post-rally warrants monitoring. The stock offers growth potential if execution continues, but investors should weigh margin pressures against expansion prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
